FDA Asks: How Do You Paper-Trail Your Medicated Moo Juice?
Published Date: 2/25/2026
Notice
Summary
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
Licensed Feedmills: Large recordkeeping burden
If you run a registered, licensed commercial medicated feed mill, you must establish, maintain, and retain records under 21 CFR part 225 documenting receipts, inventory of drug components, batch production, laboratory assay results, labels, and product distribution. FDA estimates for these registered licensed commercial feed mills a total of 2,241,792 annual responses and 683,747 total annual recordkeeping hours (average 18.3 minutes or 0.305 hours per response).
Non‑licensed Mixer/Feeders: recordkeeping hours
If you run a nonregistered, non‑licensed mixer/feeder that produces medicated feeds, you must keep records under 21 CFR part 225 for components, lab controls, labeling, production, and distribution. FDA estimates 3,400 such recordkeepers producing 309,400 total annual records and requiring 420,784 total annual hours (average 1.36 hours per record).
Non‑licensed Commercial Feedmills: recordkeeping needs
If you operate a nonregistered, non‑licensed commercial feed mill that manufactures medicated feeds, you must keep records under 21 CFR part 225 for components, laboratory controls, packaging and labeling, production, and distribution. FDA estimates 1,658 recordkeepers with 150,878 total annual records and 217,265 total annual hours (average 1.44 hours per record).
Type A Medicated Article Makers: hourly burden
If you manufacture Type A medicated articles under 21 CFR part 226, you must keep records for premix components, laboratory controls, packaging, master formulas, batch production, distribution, and complaint files. FDA estimates 65 respondents generating 89,050 annual responses with about 89,050 total annual hours (approximately 1 hour per response).
FDA lowers estimated paperwork burden
FDA reports it adjusted its inventory and reduced the estimated number of medicated‑feed recordkeepers by 2,722, resulting in a decrease of 13,731,017 records and a decrease of 913,153 total annual recordkeeping hours. This change updates the compliance burden estimate for affected manufacturers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03771 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Retailer Training Programs
The FDA is asking for public feedback on their plan to keep collecting info about tobacco retailer training programs. These programs help stores teach employees the rules about selling tobacco safely and legally. If approved, this will continue without extra costs but keep the training standards clear and up-to-date. Comments are due by March 27, 2026, so retailers and the public can weigh in!
Next: 2026-03773 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing.
The FDA wants to hear from companies that make biological products and human tissues about how they report mistakes during manufacturing. They’re asking for feedback on updating the forms and rules to keep things clear and safe. If you’re involved in making these products, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just a chance to help improve the process!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in